26 completed, 7 terminated, 2 active not recruiting. 22 Phase 1, 12 Phase 2, 2 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 22 | Completed 15, Terminated 6, Active not recruiting 1 |
| Phase 2 | 12 | Completed 9, Terminated 3 |
| Not applicable | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma: new trials by email Literature Review of Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma trials Research Report on Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma Brentuximab Vedotin, Laboratory Biomarker Analysis, Lenalidomide - Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Completed | John Reneau | 26 | 2018-03-16 | 2026-08-13 |
| Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma Anti-ICOS Monoclonal Antibody MEDI-570, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2016-09-13 | 2026-06-26 |
| Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma romidepsin, lenalidomide, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | Northwestern University | 30 | 2015-06-11 | 2026-06-12 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma carfilzomib, romidepsin, laboratory biomarker analysis - Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome | Phase 1 | Terminated | Northwestern University | 7 | 2013-03-22 | 2019-08-29 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant infection prophylaxis and management, laboratory biomarker analysis, flow cytometry - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Active not recruiting | City of Hope Medical Center | 153 | 2011-01-11 | 2026-10-22 | |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors gamma-secretase/Notch signalling pathway inhibitor RO4929097, capecitabine, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2010-06-01 | 2014-11-07 |
| AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma Pharmacodynamic Studies, Fatigue Inventory, Pharmacogenomic studies - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Amir Mortazavi | 44 | 2010-05-04 | 2018-06-04 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer massage therapy, questionnaire administration, quality-of-life assessment - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Not applicable | Completed | Wake Forest University Health Sciences | 80 | 2010-04-01 | 2018-07-02 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer rituximab, mycophenolate mofetil, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Terminated | University of Nebraska | 20 | 2009-12-10 | 2023-09-06 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma 2'-F-ara-deoxyuridine, positron emission tomography, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2009-07-01 | 2014-01-07 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Dasatinib, Pharmacological Study - Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 80 | 2008-10-01 | 2015-07-02 |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma vorinostat, rituximab, ifosfamide - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Washington | 29 | 2007-12-01 | 2017-05-25 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction vorinostat, pharmacological study - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 2007-06-01 | 2014-02-24 |
| Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer beclomethasone dipropionate, placebo, tacrolimus - Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 140 | 2007-04-01 | 2021-02-03 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma gemcitabine hydrochloride, triapine - Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2006-06-01 | 2013-09-30 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma tanespimycin, belinostat, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2006-05-01 | 2013-05-16 |
Showing 20 of 35. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (35) · Mycosis Fungoides (33) · Sezary Syndrome (32) · Burkitt Lymphoma (29) · Leukemia, Lymphocytic, Chronic, B-Cell (29) · Lymphoma, Follicular (29) · Lymphoma, Large B-Cell, Diffuse (29) · Lymphoma, B-Cell, Marginal Zone (28) · Lymphoma, Large-Cell, Anaplastic (28) · Lymphoma, Mantle-Cell (28) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (28) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (28) · Hodgkin Disease (27) · Immunoblastic Lymphadenopathy (27) · Lymphoma, Non-Hodgkin (27)
Hemic and Lymphatic Diseases (35) · Immune System Diseases (35) · Immunoproliferative Disorders (35) · Lymphatic Diseases (35) · Lymphoproliferative Disorders (35) · Neoplasms (35) · Neoplasms by Histologic Type (35) · Lymphoma (34) · Lymphoma, T-Cell (32) · Hematologic Diseases (30) · Leukemia, Lymphoid (30) · Chronic Disease (29) · DNA Virus Infections (29) · Disease Attributes (29) · Herpesviridae Infections (29)
Mycophenolic Acid (5) · Whole-Body Irradiation (5) · fludarabine phosphate (5) · Peripheral Blood Stem Cell Transplantation (4) · Tacrolimus (4) · Cyclophosphamide (3) · Rituximab (3) · tanespimycin (3) · Bortezomib (2) · Brentuximab Vedotin (2) · Busulfan (2) · Cyclosporine (2) · Etoposide (2) · Gemcitabine (2) · Gene Expression Profiling (2)
National Cancer Institute (NCI) (18) · Fred Hutchinson Cancer Center (5) · Northwestern University (3) · City of Hope Medical Center (2) · Wake Forest University Health Sciences (2) · Amir Mortazavi (1) · Case Comprehensive Cancer Center (1) · John Reneau (1) · University of Nebraska (1) · University of Washington (1)
United States (35) · Canada (2) · Italy (2)
Ramesh Ramanathan (2) · Ryotaro Nakamura (2) · Adam Petrich, MD (1) · Alain Rook (1) · Amir Mortazavi, MD (1) · Ann Woolfrey (1) · Barbara Pro, MD (1) · Brenda Sandmaier (1) · Brian Hill, MD (1) · Chandra Belani (1) · Charles Erlichman (1) · David Maloney (1) · George Wilding (1) · Janet Tooze, PhD (1)
PMID 18698002, PMID 19900571, PMID 26853648, PMID 26943915, PMID 28270022, PMID 30562587, PMID 32499241, PMID 32632956, PMID 33492438, PMID 36826995, PMID 37327113
U01CA062491 (4), U01CA099168 (4), P30CA015704 (3), U01CA062487 (3), P01CA018029 (2), U01CA062502 (2), U01CA062505 (2), U01CA069912 (2), N01CM62208 (1), P01CA078902 (1), P30CA014520 (1), P30CA015083 (1), P30CA016058 (1), P30CA022453 (1), P30CA036727 (1)